Daebongls.Co.Ltd

KQ:078140 Korea Pharmaceuticals
Market Cap
$77.84 Million
₩113.97 Billion KRW
Market Cap Rank
#22558 Global
#1158 in Korea
Share Price
₩10280.00
Change (1 day)
+1.78%
52-Week Range
₩9930.00 - ₩15380.00
All Time High
₩23750.00
Categories
Companies in Korea Pharmaceuticals
About

Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally. The company's Cosmetic Ingredients division offers special cosmetic ingredients comprising fresh green tea, black ginseng water, jeju hatban extract, wormwood extract, jeju camellia oil, jeju dang oil extract, jeju basalt po… Read more

Daebongls.Co.Ltd (078140) - Net Assets

Latest net assets as of September 2025: ₩176.09 Billion KRW

Based on the latest financial reports, Daebongls.Co.Ltd (078140) has net assets worth ₩176.09 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩255.44 Billion) and total liabilities (₩79.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩176.09 Billion
% of Total Assets 68.94%
Annual Growth Rate 10.36%
5-Year Change 27.0%
10-Year Change 138.76%
Growth Volatility 10.39

Daebongls.Co.Ltd - Net Assets Trend (2011–2024)

This chart illustrates how Daebongls.Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Daebongls.Co.Ltd (2011–2024)

The table below shows the annual net assets of Daebongls.Co.Ltd from 2011 to 2024.

Year Net Assets Change
2024-12-31 ₩131.77 Billion -14.01%
2023-12-31 ₩153.23 Billion +30.79%
2022-12-31 ₩117.16 Billion +7.09%
2021-12-31 ₩109.40 Billion +5.45%
2020-12-31 ₩103.75 Billion +28.39%
2019-12-31 ₩80.81 Billion +8.29%
2018-12-31 ₩74.62 Billion +7.79%
2017-12-31 ₩69.23 Billion +10.03%
2016-12-31 ₩62.92 Billion +14.02%
2015-12-31 ₩55.19 Billion +11.81%
2014-12-31 ₩49.36 Billion +11.55%
2013-12-31 ₩44.25 Billion +11.89%
2012-12-31 ₩39.54 Billion +8.17%
2011-12-31 ₩36.56 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Daebongls.Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 9841565277000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩98.42 Billion 74.69%
Common Stock ₩5.54 Billion 4.21%
Other Components ₩27.81 Billion 21.10%
Total Equity ₩131.77 Billion 100.00%

Daebongls.Co.Ltd Competitors by Market Cap

The table below lists competitors of Daebongls.Co.Ltd ranked by their market capitalization.

Company Market Cap
Railcare Group AB (publ)
ST:RAIL
 		$37.71 Million
Chinyang Hold
KO:100250
 		$37.72 Million
Texmaco Infrastructure & Holdings Limited
NSE:TEXINFRA
 		$37.72 Million
MSM Malaysia Holdings Bhd
KLSE:5202
 		$37.72 Million
Kingstate Electronics
TWO:3206
 		$37.70 Million
Arihant Superstructures Limited
NSE:ARIHANTSUP
 		$37.69 Million
Otello Corporation ASA
PINK:OPESF
 		$37.69 Million
Opnet Technologies Co Ltd
TWO:8034
 		$37.68 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Daebongls.Co.Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 120,726,877,310 to 131,765,092,540, a change of 11,038,215,230 (9.1%).
  • Net income of 7,339,459,130 contributed positively to equity growth.
  • Dividend payments of 926,491,080 reduced retained earnings.
  • Share repurchases of 2,385,676,500 reduced equity.
  • Other factors increased equity by 7,010,923,680.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩7.34 Billion +5.57%
Dividends Paid ₩926.49 Million -0.7%
Share Repurchases ₩2.39 Billion -1.81%
Other Changes ₩7.01 Billion +5.32%
Total Change ₩- 9.14%

Book Value vs Market Value Analysis

This analysis compares Daebongls.Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.85x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.81x to 0.85x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩5675.50 ₩10280.00 x
2017-12-31 ₩6244.51 ₩10280.00 x
2018-12-31 ₩6731.03 ₩10280.00 x
2019-12-31 ₩7288.94 ₩10280.00 x
2020-12-31 ₩9423.16 ₩10280.00 x
2021-12-31 ₩9992.64 ₩10280.00 x
2022-12-31 ₩10701.07 ₩10280.00 x
2023-12-31 ₩11027.13 ₩10280.00 x
2024-12-31 ₩12035.35 ₩10280.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Daebongls.Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 5.57%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.81%
  • • Asset Turnover: 0.39x
  • • Equity Multiplier: 1.81x
  • Recent ROE (5.57%) is below the historical average (8.58%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 8.65% 8.29% 0.87x 1.20x ₩-493.19 Million
2012 8.58% 7.59% 0.95x 1.19x ₩-556.92 Million
2013 11.43% 11.41% 0.86x 1.17x ₩624.52 Million
2014 11.21% 10.44% 0.92x 1.17x ₩586.93 Million
2015 12.96% 12.19% 0.90x 1.19x ₩1.63 Billion
2016 13.33% 11.81% 0.94x 1.20x ₩2.10 Billion
2017 10.31% 10.87% 0.82x 1.16x ₩216.10 Million
2018 8.34% 8.66% 0.83x 1.16x ₩-1.24 Billion
2019 7.09% 8.24% 0.68x 1.26x ₩-2.35 Billion
2020 5.61% 7.63% 0.51x 1.44x ₩-4.55 Billion
2021 6.21% 8.18% 0.51x 1.49x ₩-4.15 Billion
2022 7.36% 9.23% 0.50x 1.59x ₩-3.09 Billion
2023 3.46% 4.77% 0.45x 1.61x ₩-7.89 Billion
2024 5.57% 7.81% 0.39x 1.81x ₩-5.84 Billion

Industry Comparison

This section compares Daebongls.Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $96,196,506,488
  • Average return on equity (ROE) among peers: -9.52%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Daebongls.Co.Ltd (078140) ₩176.09 Billion 8.65% 0.45x $37.71 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Sam-A Pharm. Co. Ltd (009300) $148.92 Billion 6.63% 0.09x $21.27 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $257.20 Billion 4.73% 0.21x $50.06 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million